Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

The wobbly status of ketolides: where do we stand?

Georgopapadakou NH.

Expert Opin Investig Drugs. 2014 Oct;23(10):1313-9. doi: 10.1517/13543784.2014.954036. Epub 2014 Aug 25.

PMID:
25154307
2.

Prospects for new antibacterials: can we do better?

Georgopapadakou NH.

Expert Opin Investig Drugs. 2014 Feb;23(2):145-8. doi: 10.1517/13543784.2014.847087. Epub 2013 Nov 11.

PMID:
24205783
3.

Anticancer therapeutics: a surge of new developments increasingly target tumor and stroma.

Broxterman HJ, Georgopapadakou NH.

Drug Resist Updat. 2007 Aug-Oct;10(4-5):182-93. Epub 2007 Sep 12.

PMID:
17855157
4.

Fungal diagnostics, pathogenesis and chemotherapy symposia.

Georgopapadakou NH.

IDrugs. 1998 Dec;1(8):841-2.

PMID:
16196467
5.

Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.

Broxterman HJ, Georgopapadakou NH.

Drug Resist Updat. 2005 Aug;8(4):183-97. Epub 2005 Sep 9.

PMID:
16154800
6.

Beta-lactamase inhibitors: evolving compounds for evolving resistance targets.

Georgopapadakou NH.

Expert Opin Investig Drugs. 2004 Oct;13(10):1307-18. Review.

PMID:
15461559
7.

New cancer therapeutics: target-specific in, cytotoxics out?

Broxterman HJ, Georgopapadakou NH.

Drug Resist Updat. 2004 Apr;7(2):79-87.

PMID:
15158764
8.

Mechanism of action of NB2001 and NB2030, novel antibacterial agents activated by beta-lactamases.

Stone GW, Zhang Q, Castillo R, Doppalapudi VR, Bueno AR, Lee JY, Li Q, Sergeeva M, Khambatta G, Georgopapadakou NH.

Antimicrob Agents Chemother. 2004 Feb;48(2):477-83.

9.

Infectious disease 2001: drug resistance, new drugs.

Georgopapadakou NH.

Drug Resist Updat. 2002 Oct;5(5):181-91.

PMID:
12450783
10.

A diversity of therapeutic targets.

Georgopapadakou NH.

Expert Opin Ther Targets. 2002 Jun;6(3):255-6. No abstract available.

PMID:
12223067
11.

Antifungals targeted to protein modification: focus on protein N-myristoyltransferase.

Georgopapadakou NH.

Expert Opin Investig Drugs. 2002 Aug;11(8):1117-25. Review.

PMID:
12150705
12.

A continuous fluorometric assay of myristoyl-coenzyme A:protein N-myristoyltransferase.

Pennise CR, Georgopapadakou NH, Collins RD, Graciani NR, Pompliano DL.

Anal Biochem. 2002 Jan 15;300(2):275-7. No abstract available.

PMID:
11779123
13.

39(th)Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) San Francisco, USA, 26-29 September 1999.

Georgopapadakou NH.

Drug Resist Updat. 1999 Oct;2(5):335-340. No abstract available.

PMID:
11504508
14.

EDITORIAL.

Georgopapadakou NH, Broxterman H, Chambers H, Cowman AF, Wainberg M.

Drug Resist Updat. 1999 Feb;2(1):1. No abstract available.

PMID:
11504462
15.

Infectious disease 2000: drug resistance and new drugs.

Georgopapadakou NH.

Drug Resist Updat. 2000 Oct;3(5):265-269.

PMID:
11498394
16.

Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors.

Georgopapadakou NH.

Expert Opin Investig Drugs. 2001 Feb;10(2):269-80. Review.

PMID:
11178340
17.

Antifungals targeted to sphingolipid synthesis: focus on inositol phosphorylceramide synthase.

Georgopapadakou NH.

Expert Opin Investig Drugs. 2000 Aug;9(8):1787-96. Review.

PMID:
11060777
18.

Inhibition of inositol phosphorylceramide synthase by aureobasidin A in Candida and Aspergillus species.

Zhong W, Jeffries MW, Georgopapadakou NH.

Antimicrob Agents Chemother. 2000 Mar;44(3):651-3.

19.

Inhibition of yeast inositol phosphorylceramide synthase by aureobasidin A measured by a fluorometric assay.

Zhong W, Murphy DJ, Georgopapadakou NH.

FEBS Lett. 1999 Dec 17;463(3):241-4.

20.

Antifungals: mechanism of action and resistance, established and novel drugs.

Georgopapadakou NH.

Curr Opin Microbiol. 1998 Oct;1(5):547-57. Review.

PMID:
10066533
21.

Antifungals targeted to the cell wall.

Georgopapadakou NH.

Expert Opin Investig Drugs. 1997 Feb;6(2):147-50.

PMID:
15989597
22.

Mammalian microsomal and soluble Ras-processing peptidase activities are distinct.

Hitz AM, Georgopapadakou NH.

FEBS Lett. 1996 Aug 12;391(3):310-2.

23.

Does cephalothin inhibit matrix metalloproteinases?

Georgopapadakou NH.

Antimicrob Agents Chemother. 1996 Aug;40(8):1969-70. No abstract available.

24.

Antifungal agents: chemotherapeutic targets and immunologic strategies.

Georgopapadakou NH, Walsh TJ.

Antimicrob Agents Chemother. 1996 Feb;40(2):279-91. Review. No abstract available.

25.

Inhibitors of farnesyltransferase and Ras processing peptidase.

Hall CC, Watkins JD, Ferguson SB, Foley LH, Georgopapadakou NH.

Biochem Biophys Res Commun. 1995 Dec 26;217(3):728-32.

PMID:
8554591
26.

The fungal cell wall as a drug target.

Georgopapadakou NH, Tkacz JS.

Trends Microbiol. 1995 Mar;3(3):98-104. Review.

PMID:
7773595
27.

Low-level resistance to the cephalosporin 3'-quinolone ester Ro 23-9424 in Escherichia coli.

Chapman JS, Bertasso A, Cummings LM, Georgopapadakou NH.

Antimicrob Agents Chemother. 1995 Feb;39(2):564-6.

28.

A radiometric assay for Ras-processing peptidase using an enzymatically radiolabeled peptide.

Georgopapadakou NH, Hall CC, Lambros T, Liu W, Watkins JD.

Anal Biochem. 1994 May 1;218(2):273-7.

PMID:
8074280
29.

beta-Lactamase hydrolysis of cephalosporin 3'-quinolone esters, carbamates, and tertiary amines.

Georgopapadakou NH, McCaffrey C.

Antimicrob Agents Chemother. 1994 May;38(5):959-62.

30.

Human mycoses: drugs and targets for emerging pathogens.

Georgopapadakou NH, Walsh TJ.

Science. 1994 Apr 15;264(5157):371-3. Review. No abstract available.

PMID:
8153622
31.

Dual-action cephalosporins incorporating a 3'-tertiary-amine-linked quinolone.

Albrecht HA, Beskid G, Christenson JG, Deitcher KH, Georgopapadakou NH, Keith DD, Konzelmann FM, Pruess DL, Wei CC.

J Med Chem. 1994 Feb 4;37(3):400-7.

PMID:
8308866
32.

Penicillin-binding proteins and bacterial resistance to beta-lactams.

Georgopapadakou NH.

Antimicrob Agents Chemother. 1993 Oct;37(10):2045-53. Review. No abstract available.

33.

Porins and lipopolysaccharide of Escherichia coli ATCC 25922 and isogenic rough mutants.

Rivera M, Bertasso A, McCaffrey C, Georgopapadakou NH.

FEMS Microbiol Lett. 1993 Apr 1;108(2):183-7.

PMID:
8387443
34.

Mechanisms of action of cephalosporin 3'-quinolone esters, carbamates, and tertiary amines in Escherichia coli.

Georgopapadakou NH, Bertasso A.

Antimicrob Agents Chemother. 1993 Mar;37(3):559-65.

35.

Screening assays for protein synthesis inhibitors.

Hall CC, Bertasso A, Watkins JD, Georgopapadakou NH.

J Antibiot (Tokyo). 1992 Oct;45(10):1697-9. No abstract available.

36.

Effects of squalene epoxidase inhibitors on Candida albicans.

Georgopapadakou NH, Bertasso A.

Antimicrob Agents Chemother. 1992 Aug;36(8):1779-81.

37.

Quinolone accumulation in Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus.

McCaffrey C, Bertasso A, Pace J, Georgopapadakou NH.

Antimicrob Agents Chemother. 1992 Aug;36(8):1601-5.

38.

Dual-action penems and carbapenems.

Corraz AJ, Dax SL, Dunlap NK, Georgopapadakou NH, Keith DD, Pruess DL, Rossman PL, Then R, Unowsky J, Wei CC.

J Med Chem. 1992 May 15;35(10):1828-39.

PMID:
1588561
39.

Effects of quinolones on nucleoid segregation in Escherichia coli.

Georgopapadakou NH, Bertasso A.

Antimicrob Agents Chemother. 1991 Dec;35(12):2645-8.

40.
41.

Dual-action cephalosporins: cephalosporin 3'-quinolone carbamates.

Albrecht HA, Beskid G, Christenson JG, Georgopapadakou NH, Keith DD, Konzelmann FM, Pruess DL, Rossman PL, Wei CC.

J Med Chem. 1991 Sep;34(9):2857-64.

PMID:
1910090
42.
43.

Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.

Albrecht HA, Beskid G, Christenson JG, Durkin JW, Fallat V, Georgopapadakou NH, Keith DD, Konzelmann FM, Lipschitz ER, McGarry DH, et al.

J Med Chem. 1991 Feb;34(2):669-75.

PMID:
1847430
44.

Antibiotic permeation through the bacterial outer membrane.

Georgopapadakou NH.

J Chemother. 1990 Oct;2(5):275-9. Review. No abstract available.

PMID:
1965316
45.

Cephalosporin 3'-quinolone esters with a dual mode of action.

Albrecht HA, Beskid G, Chan KK, Christenson JG, Cleeland R, Deitcher KH, Georgopapadakou NH, Keith DD, Pruess DL, Sepinwall J, et al.

J Med Chem. 1990 Jan;33(1):77-86.

PMID:
2153215
46.

Mode of action of the dual-action cephalosporin Ro 23-9424.

Georgopapadakou NH, Bertasso A, Chan KK, Chapman JS, Cleeland R, Cummings LM, Dix BA, Keith DD.

Antimicrob Agents Chemother. 1989 Jul;33(7):1067-71.

47.

Effects of elfamycins on elongation factor Tu from Escherichia coli and Staphylococcus aureus.

Hall CC, Watkins JD, Georgopapadakou NH.

Antimicrob Agents Chemother. 1989 Mar;33(3):322-5.

48.

Fleroxacin resistance in Escherichia coli.

Chapman JS, Bertasso A, Georgopapadakou NH.

Antimicrob Agents Chemother. 1989 Feb;33(2):239-41.

49.

Fluorometric assay for fleroxacin uptake by bacterial cells.

Chapman JS, Georgopapadakou NH.

Antimicrob Agents Chemother. 1989 Jan;33(1):27-9.

50.

Routes of quinolone permeation in Escherichia coli.

Chapman JS, Georgopapadakou NH.

Antimicrob Agents Chemother. 1988 Apr;32(4):438-42.

Supplemental Content

Loading ...
Support Center